Truist Securities Upgrades Biogen (BIIB) to Buy
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $216.73 -0.19%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 48
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 20 | New: 48
Join SI Premium – FREE
Truist Securities analyst Danielle Brill upgraded Biogen (NASDAQ: BIIB) from Hold to Buy with a price target of $235.00.
For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.
Shares of Biogen closed at $199.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle Starts A New Round Of Layoffs - Business Insider
- Cantor Fitzgerald Reiterates Overweight Rating on Pharvaris B.V. (PHVS)
- UBS Reiterates Buy Rating on Diamondback Energy (FANG)
Create E-mail Alert Related Categories
UpgradesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
